ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma
- 10 June 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 489, 121-132
- https://doi.org/10.1016/j.canlet.2020.06.002
Abstract
No abstract availableKeywords
Funding Information
- Cancerfonden
- Japan Society for the Promotion of Science
- Takeda Science Foundation
This publication has 35 references indexed in Scilit:
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapyNature, 2015
- NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomasInternational Journal of Cancer, 2015
- Serum chemokine network correlates with chemotherapy in non-small cell lung cancerCancer Letters, 2015
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Involvement of CCR6/CCL20/IL-17 Axis in NSCLC Disease ProgressionPLOS ONE, 2011
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaJournal of Thoracic Oncology, 2011
- T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor ImmunityImmunity, 2009
- Thyroid Transcription Factor-1 Inhibits Transforming Growth Factor-β–Mediated Epithelial-to-Mesenchymal Transition in Lung Adenocarcinoma CellsCancer Research, 2009
- Roles of Achaete-Scute Homologue 1 in DKK1 and E-cadherin Repression and Neuroendocrine Differentiation in Lung CancerCancer Research, 2008
- ASH1 Gene Is a Specific Therapeutic Target for Lung Cancers with Neuroendocrine FeaturesCancer Research, 2005